FinanceAsianet Newsable
FDA panel backs Hims peptides; stock rises, Shkreli shorts
in5points
HIMS stock rose overnight after an FDA advisory panel backed four peptides.
‘Pharma Bro’ Martin Shkreli went short on HIMS stock.
Leerink estimates a $2.2 billion peptide market with Hims potentially capturing about 20%.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically